A multicentric randomized controlled trial on the impact of lengthening the interval between neoadjuvant radiochemotherapy and surgery on complete pathological response in rectal cancer (GRECCAR-6 trial): Rationale and design

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Lefevre, Jérémie H ^a,b   Rousseau, Alexandra ^a   Svrcek, Magali ^a,b   Parc, Yann ^a,b   Simon, Tabassome ^a,b   Tiret, Emmanuel ^a,b  

^a HÔPITAL SAINT ANTOINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Complete histological response; Procedure; Radiochemotherapy; Rectal cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMORADIOTHERAPY; ARTICLE; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HEALTH CARE QUALITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MESORECTAL EXCISION; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PATIENT CARE; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; RECTUM SURGERY; SURGICAL TECHNIQUE; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE;

CHEMORADIOTHERAPY; FOLLOW-UP STUDIES; HUMANS; NEOADJUVANT THERAPY; RECTAL NEOPLASMS; REMISSION INDUCTION; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84883700809     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-417     Document Type: Article

References (44)

1. Bouvier AM, Remontet L, Jougla E. Incidence of gastrointestinal cancers in France. Gastroenterol Clin Biol 2004, 28:877-881. 10.1016/S0399-8320(04)95152-4, 15523225.
2. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986, 1(8496):1479-1482.
3. MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet 1993, 341(8843):457-460. 10.1016/0140-6736(93)90207-W, 8094488.
4. Martling A, Cedermark B, Johansson H, Rutqvist LE, Holm T. The surgeon as a prognostic factor after the introduction of total mesorectal excision in the treatment of rectal cancer. Br J Surg 2002, 89(8):1008-1013. 10.1046/j.1365-2168.2002.02151.x, 12153626.
5. Martling A, Holm T, Rutqvist LE, Johansson H, Moran BJ, Heald RJ, Cedermark B. Impact of a surgical training programme on rectal cancer outcomes in Stockholm. Br J Surg 2005, 92(2):225-229. 10.1002/bjs.4834, 15609382.
6. Gerard A, Berrod JL, Pene F, Loygue J, Laugier A, Bruckner R, Camelot G, Arnaud JP, Metzger U, Buyse M, et al. Preoperative radiotherapy and radical surgery as combined treatment in rectal cancer. Recent Results Cancer Res 1988, 110:130-133. 10.1007/978-3-642-83293-2_19, 3043588.
7. Stockholm Rectal Cancer Study Group Preoperative short-term radiation therapy in operable rectal carcinoma. A prospective randomized trial. Cancer 1990, 66(1):49-55. Stockholm Rectal Cancer Study Group.
8. Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer. Medical research council rectal cancer working party. Lancet 1996, 348(9042):1605-1610.
9. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish rectal cancer trial. N Engl J Med 1997, 336(14):980-987.
10. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001, 345(9):638-646. 10.1056/NEJMoa010580, 11547717.
11. Marijnen CA, Kapiteijn E, van de Velde CJ, Martijn H, Steup WH, Wiggers T, Kranenbarg EK, Leer JW. Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 2002, 20(3):817-825. 10.1200/JCO.20.3.817, 11821466.
12. Peeters KC, van de Velde CJ, Leer JW, Martijn H, Junggeburt JM, Kranenbarg EK, Steup WH, Wiggers T, Rutten HJ, Marijnen CA. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients-a Dutch colorectal cancer group study. J Clin Oncol 2005, 23(25):6199-6206. 10.1200/JCO.2005.14.779, 16135487.
13. Portier G. [Recommendations for clinical practice. Therapeutic choices for rectal cancer. How should neoadjuvant therapies be chosen?]. Gastroenterol Clin Biol 2007, 31 Spec No 1:23-33.
14. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006, 355(11):1114-1123. 10.1056/NEJMoa060829, 16971718.
15. Bosset JF, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Briffaux A, Collette L. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results-EORTC 22921. J Clin Oncol 2005, 23(24):5620-5627. 10.1200/JCO.2005.02.113, 16009958.
16. Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U, Silva e Sousa AH, Campos FG, Kiss DR, Gama-Rodrigues J. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004, 240(4):711-717. 1356472, 15383798.
17. de Campos-Lobato LF, Stocchi L, da Luz MA, Geisler D, Dietz DW, Lavery IC, Fazio VW, Kalady MF. Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence. Ann Surg Oncol 2011, 18(6):1590-1598. 10.1245/s10434-010-1506-1, 21207164.
18. Medich D, McGinty J, Parda D, Karlovits S, Davis C, Caushaj P, Lembersky B. Preoperative chemoradiotherapy and radical surgery for locally advanced distal rectal adenocarcinoma: pathologic findings and clinical implications. Dis Colon Rectum 2001, 44(8):1123-1128. 10.1007/BF02234632, 11535851.
19. Kim NK, Baik SH, Seong JS, Kim H, Roh JK, Lee KY, Sohn SK, Cho CH. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: impact of postirradiated pathologic downstaging on local recurrence and survival. Ann Surg 2006, 244(6):1024-1030. 10.1097/01.sla.0000225360.99257.73, 1856621, 17122629.
20. Hiotis SP, Weber SM, Cohen AM, Minsky BD, Paty PB, Guillem JG, Wagman R, Saltz LB, Wong WD. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg 2002, 194(2):131-135. discussion 135-136, 10.1016/S1072-7515(01)01159-0, 11848629.
21. Francois Y, Nemoz CJ, Baulieux J, Vignal J, Grandjean JP, Partensky C, Souquet JC, Adeleine P, Gerard JP. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 1999, 17(8):2396.
22. Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005, 23(34):8688-8696. 10.1200/JCO.2005.02.1329, 16246976.
23. Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006, 24(28):4620-4625. 10.1200/JCO.2006.06.7629, 17008704.
24. Stipa F, Chessin DB, Shia J, Paty PB, Weiser M, Temple LK, Minsky BD, Wong WD, Guillem JG. A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography. Ann Surg Oncol 2006, 13(8):1047-1053. 10.1245/ASO.2006.03.053, 16865595.
25. Garcia-Aguilar J, Hernandez de Anda E, Sirivongs P, Lee SH, Madoff RD, Rothenberger DA. A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum 2003, 46(3):298-304. 10.1007/s10350-004-6545-x, 12626903.
26. Ruo L, Tickoo S, Klimstra DS, Minsky BD, Saltz L, Mazumdar M, Paty PB, Wong WD, Larson SM, Cohen AM, et al. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg 2002, 236(1):75-81. 10.1097/00000658-200207000-00012, 1422551, 12131088.
27. Moore HG, Gittleman AE, Minsky BD, Wong D, Paty PB, Weiser M, Temple L, Saltz L, Shia J, Guillem JG. Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum 2004, 47(3):279-286. 10.1007/s10350-003-0062-1, 14991488.
28. Stein DE, Mahmoud NN, Anne PR, Rose DG, Isenberg GA, Goldstein SD, Mitchell E, Fry RD. Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma. Dis Colon Rectum 2003, 46(4):448-453. 10.1007/s10350-004-6579-0, 12682535.
29. Tulchinsky H, Shmueli E, Figer A, Klausner JM, Rabau M. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol 2008, 15(10):2661-2667. 10.1245/s10434-008-9892-3, 18389322.
30. Kalady MF, de Campos-Lobato LF, Stocchi L, Geisler DP, Dietz D, Lavery IC, Fazio VW. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg 2009, 250(4):582-589.
31. Lim SB, Choi HS, Jeong SY, Kim DY, Jung KH, Hong YS, Chang HJ, Park JG. Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers. Ann Surg 2008, 248(2):243-251. 10.1097/SLA.0b013e31817fc2a0, 18650634.
32. Yeo SG, Kim DY, Kim TH, Chang HJ, Oh JH, Park W, Choi DH, Nam H, Kim JS, Cho MJ, et al. Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer: long-term outcomes and prognostic significance of pathologic nodal status (KROG 09-01). Ann Surg 2010, 252(6):998-1004. 10.1097/SLA.0b013e3181f3f1b1, 21107110.
33. de Campos-Lobato LF, Geisler DP, da Luz MA, Stocchi L, Dietz D, Kalady MF. Neoadjuvant therapy for rectal cancer: the impact of longer interval between chemoradiation and surgery. J Gastrointest Surg 2011, 15(3):444-450. 10.1007/s11605-010-1197-8, 21140237.
34. Bujko K. Timing of surgery following preoperative therapy in rectal cancer: there is no need for a prospective randomized trial. Dis Colon Rectum 2012, 55(3):31-32.
35. Rullier A, Laurent C. [Recommendations for clinical practice. Therapeutic choices for rectal cancer. What quality criteria are important for surgical excision of rectal cancer?]. Gastroenterol Clin Biol 2007, 31 Spec No 1:34-51. 31S91-35.
36. Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 1986, 2(8514):996-999.
37. Tranchart H, Lefevre JH, Svrcek M, Flejou JF, Tiret E, Parc Y. What is the incidence of metastatic lymph node involvement after significant pathologic response of primary tumor following neoadjuvant treatment for locally advanced rectal cancer?. Ann Surg Oncol 2012, 20(5):1551-1559.
38. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997, 12(1):19-23. 10.1007/s003840050072, 9112145.
39. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibanes E, Pekolj J, Slankamenac K, Bassi C, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009, 250(2):187-196. 10.1097/SLA.0b013e3181b13ca2, 19638912.
40. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004, 240(2):205-213. 10.1097/01.sla.0000133083.54934.ae, 1360123, 15273542.
41. Armitage P. Interim analysis in clinical trials. Stat Med 1991, 10(6):925-935. discussion 936-927, 10.1002/sim.4780100613, 1876782.
42. Kramar A, Mathoulin-Pelissier S. Methodes biostatistiques appliquées à la recherche clinique en cancérologie 2011, Paris: John Libbey Eurotext.
43. Evans J, Tait D, Swift I, Pennert K, Tekkis P, Wotherspoon A, Chau I, Cunningham D, Brown G. Timing of surgery following preoperative therapy in rectal cancer: the need for a prospective randomized trial?. Dis Colon Rectum 2011, 54(10):1251-1259. 10.1097/DCR.0b013e3182281f4b, 21904139.
44. Methy N, Bedenne L, Conroy T, Bouche O, Chapet O, Ducreux M, Gerard JP, Bonnetain F. Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial. Ann Oncol 2010, 21(3):518-524. 10.1093/annonc/mdp340, 19759186.